Luis G Calderon

US Patent:

53164776, May 31, 1994

Filed:

May 25, 1993

Appl. No.:

8/066269

Inventors:

Luis O. Calderon - Miami FL

International Classification:

A61C 800

US Classification:

433173

Abstract:

The improvement of the present invention pertains to a frustoconical abutment intended to overcome the problem of the implant's lack of parallelism. The abutment can be of the Allen-driven type or the through-screw type. Both engage with an implant ranging from partially to totally inserted below the gingival margin. The abutment of the Allen-driven type includes a threaded cavity that receives a threaded member of a prosthesis. The through-screw abutment includes a threaded through-opening that also receives the threaded member of a prosthesis. The frustoconical abutment permits a dentist to reduce the mass to end up with a resulting shape that will correct the lack of parallelism typically created by misaligned implants and allowing for more aesthetic form which mimics a natural tooth shape. This is particularly helpful when part of the implant's end protrudes from the gingival margin instead of submerged below it.

US Patent:

20180208669, Jul 26, 2018

Filed:

Jun 15, 2015

Appl. No.:

15/319344

Inventors:

- Bethesda MD, US
- Spring House PA, US
Luis Espinoza Calderon - Bethesda MD, US
Kate Sasser - Spring House PA, US
Ricardo Attar - Spring House PA, US

Assignee:

The United States of America, as represented by th e Secretary, Dept. of Health and Human Services - Bethesda MD
Janssen Biotech, Inc. - Spring House PA

International Classification:

C07K 16/28
A61P 35/02
A61P 37/00

Abstract:

Provided herein are methods of inhibiting growth or proliferation of cells expressing CD38 by contacting the CD38-expressing cells with 1) NK cells bound to an anti-CD38 F(ab′)fragment and 2) an anti-CD38 antibody, in either order or simultaneously. Also provided herein are methods of treating or inhibiting a hyperproliferative disorder or an autoimmune disorder in a subject by administering to the subject 1) NK cells bound to an anti-CD38 F(ab′)fragment and 2) an anti-CD38 antibody, in either order or simultaneously.